Academic Publications. If the Applicant wishes to disseminate its Intellectual Property generated in the course of the Project for the purpose of scholarship, nothing in this Investment Agreement impedes such dissemination, provided the contributions of Alberta Innovates, the Ministry of Jobs, Economy and Innovation, the Government of Alberta, and the Funding Partners (if any) are acknowledged in such academic publication. Such publications may include, but are not limited to, abstracts, or presentations to a journal, editor, meeting, seminar or other third party.
Academic Publications. The Parties agree that it is part of the Applicant’s mission and policies to disseminate information and make it available for the purpose of scholarship, subject to the foregoing Section 11. Notwithstanding Section 11, the Applicant shall have the right to publish any Intellectual Property generated in the course of the Project in accordance with academic standards without restriction, provided the contributions of Alberta Innovates, the Ministry of Economic Development, Trade and Tourism, and the Government of Alberta are acknowledged in such academic publication. Such publications may include, but are not limited to, abstracts, or presentation to a journal, editor, meeting, seminar or other third party.
Academic Publications. The Principal Investigator and other members of the TAU Team shall have the right to publish the Ramot Technology and the Joint Technology in scientific publications or to present such results at scientific symposia, provided that the following procedure is followed:
9.2.1. No later than thirty (30) days prior to submission for publication of any scientific articles, abstracts or papers concerning the Ramot Technology or the Joint Technology and prior to the presentation of the same at any scientific symposia, the Principal Investigator shall send the Company a written copy of the material to be so submitted or presented, and shall allow the Company to review such submission to determine whether the publication or presentation contains subject matter for which patent protection should be sought and whether such publication includes Company Confidential Information.
9.2.2. The Company shall provide its written comments with respect to such publication or presentation within thirty (30) days following its receipt of such written material. If the Company does not provide written comments within the thirty (30) days set forth above, it shall be deemed to have approved such proposed publication or presentation.
9.2.3. If the Company, in its written comments, identifies material for which patent protection should be sought, then the Principal Investigator shall delay the submission of such publication or presentation for a further period of up to sixty (60) days from the receipt of such written comments to enable Ramot to make the necessary patent filings in accordance with Section 4.
Academic Publications. Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to Agios Intellectual Property that is subject to the Existing Third Party Agreement, the parties to such Existing Third Party Agreement may have retained the right to publish certain information, and nothing in this Section 11.4 is intended to restrict the exercise of such rights; provided that, to the extent that Agios has the right to review and comment on any such publications, Agios shall, to the extent permissible under such Existing Third Party Agreement, exercise such rights after consultation with Celgene.
Academic Publications. Licensors shall have the right to allow the Principal Investigators and other members of the Licensor Teams to publish the Research Results, if any, in scientific publications or to present such results at scientific symposia, provided that the following procedure is followed:
9.2.1. Licensors shall cause the members of the Licensor Teams to comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publications relating to the Research Results.
9.2.2. No later than thirty (30) days prior to submission for publication of any scientific articles, abstracts or papers concerning Research Results and prior to the presentation of such results at any scientific symposia, Licensors shall send to BioLine a written copy of the material to be so submitted or presented, and shall allow BioLine to review such submission to determine whether the publication or presentation contains subject matter for which patent protection should be sought prior to publication or presentation for the preservation of Licensed Patent Rights.
9.2.3. BioLine shall provide its written comments with respect to such publication or presentation within fourteen (14) days following its receipt of such written material.
9.2.4. If BioLine, in its written comments, identifies material for which patent protection should be sought, then Licensors shall cause the publication or presentation of such submission to be delayed for a further period of up to sixty (60) days from the receipt of such written comments to enable the parties, through the parties’ patent counsel to make the necessary patent filings in accordance with Section 4, provided, however, that if such counsel determines in good faith that more time is required the submission shall be delayed for an additional period of up to thirty (30) days.
9.2.5. After compliance with the foregoing procedures with respect to an academic, scientific or medical publication and/or public presentation, members of the Licensor Teams shall not have to resubmit any such information for re-approval should it be republished or publicly disclosed in another form.
Academic Publications. The Parties agree that it is part of the Applicant’s mission and policies to disseminate information and make it available for the purpose of scholarship, subject to the foregoing Section
Academic Publications. The Parties recognize that independent investigators have been engaged, and will be engaged in the future, to conduct clinical trials and studies of the Products. The Parties recognize that such investigators operate in an academic environment and may release information regarding such studies in a manner consistent with academic standards and as further provided in this paragraph. In the event that any such independent investigator of a Party desires to publish any abstract, manuscript or article or make any presentation (including verbal presentations) or other publication that includes any Confidential Information of the other Party, such Party shall (i) require such independent investigator to provide the other Party and its patent counsel the opportunity to review any proposed abstract, manuscript, article, presentation (including verbal presentations) or other publication at least thirty (30) days prior to its intended submission for publication or such presentation and (ii) upon request of the other Party not to submit any such abstract, article or manuscript for publication or not to make such presentation for such additional reasonable period of time (but not to exceed an additional thirty (30) days) to enable the other Party to secure patent protection for any material in such publication which it believes to be patentable or to consider the implications of publication on eventual commercialization.
Academic Publications. Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to Vividion Intellectual Property that is subject to an Existing Third Party Agreement, the parties to such Existing Third Party Agreement may have retained the right to publish certain information, and nothing in this Section 11.4 is intended to restrict the exercise of such rights; provided that, to the extent that Vividion has the right to review and comment on any such publications, Vividion shall, to the extent permissible under such Existing Third Party Agreement, exercise such rights after consultation with Celgene.
Academic Publications. Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to Lannett Intellectual Property that is subject to an Third Party Agreement, the parties to such Third Party Agreement may have retained the right to publish certain information, and nothing in this Section 11.4 is intended to restrict the exercise of such rights; provided that, to the extent that Lannett has the right to review and comment on any such publications, Lannett shall, to the extent permissible under such Third Party Agreement, exercise such rights after consultation with HEC.
Academic Publications. The Parties agree that it is part of the Testing Site Applicant’s mission and policies to disseminate information and make it available for the purpose of scholarship, subject to the foregoing Section 12. Notwithstanding Section 12, the Testing Site Applicant shall have the right to publish any Intellectual Property generated in the course of the Project in accordance with academic standards without restriction, provided the contributions of Alberta Innovates, the Ministry of Economic Development, Trade and Tourism, and the Government of Alberta are acknowledged in such academic publication. Such publications may include, but are not limited to, abstracts, or presentation to a journal, editor, meeting, seminar or other third party.
